Evidence map›Paper›PMID 30519742›Full record

SynthesisWorld journal of urology2019

Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials.

Matteo Ferro, Giuseppe Di Lorenzo, Ottavio de Cobelli, Dario Bruzzese, Piero Pignataro, Marco Borghesi, Gennaro Musi, Mihai Dorin Vartolomei, Vincenzo Cosimato, Alessandro Serino and 9 more

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 2 countries.

Matteo FerroDivision of Urology, European Institute of Oncology, Milan, Italy. matteo.ferro@ieo.it.ORCID http://orcid.org/0000-0002-9250-7858
Giuseppe Di LorenzoDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.
Ottavio de CobelliDivision of Urology, European Institute of Oncology, Milan, Italy.
Dario BruzzeseDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Piero PignataroDepartment of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples, Italy.
Marco BorghesiDepartment of Urology, University of Bologna, Bologna, Italy.
Gennaro MusiDivision of Urology, European Institute of Oncology, Milan, Italy.
Mihai Dorin VartolomeiDivision of Urology, European Institute of Oncology, Milan, Italy.
Vincenzo CosimatoDivision of Onco-hematology, University Hospital San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
Alessandro SerinoDivision of Urology, European Institute of Oncology, Milan, Italy.
Vincenzo IeluzziSecond University of Naples, Naples, Italy.
Daniela TerraccianoDepartment of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.
Rocco DamianoDepartment of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Francesco CantielloDepartment of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Francesco Alessandro MistrettaDivision of Urology, European Institute of Oncology, Milan, Italy.
Matteo MutoUniversity of Naples, Naples, Italy.
Giuseppe LucarelliDepartment of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.
Pietro De PlacidoDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.
Carlo BuonerbaDepartment of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy.
University of Naples Federico II · ITEuropean Institute of Oncology · ITMagna Graecia University · ITOspedali Riuniti San Giovanni di Dio e Ruggi d'Aragona · ITUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROUniversity of Bari Aldo Moro · ITUniversity of Bologna · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer-related fatigue (CRF) is a complex condition that is reported in > 50% of cancer patients. In men with castration-resistant prostate cancer (CRPC), CRF was reported in 12-21% of patients. Approved systemic therapy against CRPC is commonly administered in combination with androgen-deprivation treatment (ADT) and, in some cases, with daily, low-dose corticosteroids. Importantly, the use of low-dose corticosteroids is associated with multiple negative effects, including reduced muscle mass. On these grounds, we hypothesized that the chronic use of corticosteroids may increase the incidence of fatigue in patients with prostate cancer.

methodsWe reviewed all randomized trials published during the last 15 years conducted in patients with prostate cancer receiving systemic treatment and we performed a sub-group analysis to gather insights regarding the potential differences in the incidence of fatigue in patients receiving vs. not receiving daily corticosteroids as part of their systemic anti-neoplastic regimen.

resultsOverall, 22,734 men enrolled in prospective randomized phase II and III trials were evaluable for fatigue. Estimated pooled incidence of grade 1-2 fatigue was 30.89% (95% CI = 25.34-36.74), while estimated pooled incidence of grade 3-4 fatigue was reported in 3.90% (95% CI = 2.91-5.02). Sub-group analysis showed that grade 3-4 fatigue was approximately double in patients who received daily corticosteroids as part of their anti-neoplastic treatment (5.58; 95% CI = 4.33-6.98) vs. those who did not (2.67%; 95% CI = 1.53-4.11).

conclusionOur findings highlight the need for ad hoc-designed prospective clinical trials to investigate whether the benefits associated with low-dose, daily corticosteroids outweigh the risks associated with corticosteroid-related adverse events such as fatigue.

Indexed as

Randomized Controlled Trials as TopicAdrenal Cortex HormonesFatigueHumansIncidenceMaleProstatic NeoplasmsAdrenal Cortex HormonesCorticosteroidsFatigueMeta-analysisProstate cancer

Identifiers

PMID30519742
OpenAlexW2902649431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.